Bausch Health Companies Inc.

Bausch Health markets products directly or indirectly in approximately 90 countries, making it a globally distributed specialty healthcare business. The U.S. remains the core market for Salix and Diversified, while International covers non-U.S. sales of branded, branded generic, and OTC products. Bausch + Lomb contributes a global eye-health footprint, and the company operates about 37 manufacturing sites worldwide, including 25 Bausch + Lomb facilities. This geographic spread creates exposure to foreign exchange, local regulation, repatriation constraints, and country-specific pricing pressure. The company has also highlighted that foreign operations are subject to political and economic instability, sanctions and anti-bribery compliance, and hard-currency availability in some markets.

The company faces significant exposure to generic competition and loss of exclusivity, especially in branded pharmaceutical franchises where a single product can represent a large share of segment revenue. Its high debt load and restrictive covenants create refinancing and liquidity risk, and management explicitly notes the need to generate substantial cash to service obligations. Legal proceedings, investigations, and pricing-related scrutiny can affect both cash flow and commercial flexibility, particularly in a heavily regulated pharmaceutical environment. Because a large portion of revenue comes from international operations, the business is also exposed to foreign exchange volatility, repatriation limits, sanctions, and local political or economic instability. More broadly, healthcare reform, payer pressure, channel concentration, and product quality or regulatory compliance issues can all affect demand, margins, and access to markets.